表紙
市場調査レポート

Valeant Pharmaceuticals International, Inc. - 製品パイプライン分析

Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 224562
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
Valeant Pharmaceuticals International, Inc. - 製品パイプライン分析 Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2015
出版日: 2015年06月17日 ページ情報: 英文 48 Pages
概要

Valeant Pharmaceuticals International, Inc.は専門性の高い製薬会社として、特殊なものだけでなく、市販薬、ジェネリック薬品まで幅広い範囲の医薬品を開発・製造し、その製品を世界中に展開しています。

当レポートでは、Valeant Pharmaceuticals International, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Valeant Pharmaceuticals International, Inc.の基本情報

Valeant Pharmaceuticals International, Inc.の概要

  • 主要情報
  • 企業情報

Valeant Pharmaceuticals International, Inc.:R&Dの概要

  • 主な治療範囲

Valeant Pharmaceuticals International, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Valeant Pharmaceuticals International, Inc.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ

Valeant Pharmaceuticals International, Inc.:薬剤プロファイル

  • brimonidine tartrate
  • Product-55394
  • CB-0301
  • IDP-118
  • JNJ-10229570-AAA
  • Product-10156
  • Product-49778

Valeant Pharmaceuticals International, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Valeant Pharmaceuticals International, Inc.:最近のパイプライン動向

Valeant Pharmaceuticals International, Inc.:休止中のプロジェクト

Valeant Pharmaceuticals International, Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • ATON-004
    • CVTE-002
    • ezogabine
    • IDP-107
    • IDP-109
    • IDP-115
    • MC-5
    • pegaptanib sodium
    • RUS-350
    • taribavirin hydrochloride
    • tiazofurin
    • tramadol hydrochloride

Valeant Pharmaceuticals International, Inc.:企業発表

Valeant Pharmaceuticals International, Inc.:本社と子会社の所在地

Valeant Pharmaceuticals International, Inc.:主要製造設備

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07183CDB

Summary

Global Markets Direct's, 'Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2015', provides an overview of the Valeant Pharmaceuticals International, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Valeant Pharmaceuticals International, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Valeant Pharmaceuticals International, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Valeant Pharmaceuticals International, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Valeant Pharmaceuticals International, Inc.'s pipeline products

Reasons to buy

  • Evaluate Valeant Pharmaceuticals International, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Valeant Pharmaceuticals International, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Valeant Pharmaceuticals International, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Valeant Pharmaceuticals International, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Valeant Pharmaceuticals International, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Valeant Pharmaceuticals International, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Valeant Pharmaceuticals International, Inc. Snapshot
    • Valeant Pharmaceuticals International, Inc. Overview
    • Key Information
    • Key Facts
  • Valeant Pharmaceuticals International, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Valeant Pharmaceuticals International, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Valeant Pharmaceuticals International, Inc. - Pipeline Products Glance
    • Valeant Pharmaceuticals International, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Valeant Pharmaceuticals International, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • Valeant Pharmaceuticals International, Inc. - Drug Profiles
    • IDP-118
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • loteprednol etabonate next generation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methylnaltrexone bromide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-0301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ezogabine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PDI-192
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PDI-320
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDP-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Valeant Pharmaceuticals International, Inc. - Pipeline Analysis
    • Valeant Pharmaceuticals International, Inc. - Pipeline Products by Target
    • Valeant Pharmaceuticals International, Inc. - Pipeline Products by Route of Administration
    • Valeant Pharmaceuticals International, Inc. - Pipeline Products by Molecule Type
    • Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action
  • Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates
  • Valeant Pharmaceuticals International, Inc. - Dormant Projects
  • Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • (bupropion hydrochloride + selective serotonin reuptake inhibitor)
      • CVTE-002
      • ezogabine
      • IDP-107
      • IDP-115
      • MC-5
      • methylnaltrexone bromide
      • RUS-350
      • tiazofurin
      • UK-279276
  • Valeant Pharmaceuticals International, Inc. - Company Statement
  • Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Valeant Pharmaceuticals International, Inc., Key Information
  • Valeant Pharmaceuticals International, Inc., Key Facts
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Indication, 2015
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Stage of Development, 2015
  • Valeant Pharmaceuticals International, Inc. - Monotherapy Products in Pipeline, 2015
  • Valeant Pharmaceuticals International, Inc. - Out-Licensed Products in Pipeline, 2015
  • Valeant Pharmaceuticals International, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Valeant Pharmaceuticals International, Inc. - Phase III, 2015
  • Valeant Pharmaceuticals International, Inc. - Phase II, 2015
  • Valeant Pharmaceuticals International, Inc. - Phase I, 2015
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Target, 2015
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Route of Administration, 2015
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Molecule Type, 2015
  • Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates, 2015
  • Valeant Pharmaceuticals International, Inc. - Dormant Developmental Projects,2015
  • Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products, 2015
  • Valeant Pharmaceuticals International, Inc., Other Locations
  • Valeant Pharmaceuticals International, Inc., Subsidiaries

List of Figures

  • Valeant Pharmaceuticals International, Inc. - Pipeline by Top 10 Indication, 2015
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Stage of Development, 2015
  • Valeant Pharmaceuticals International, Inc. - Monotherapy Products in Pipeline, 2015
  • Valeant Pharmaceuticals International, Inc. - Out-Licensed Products in Pipeline, 2015
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Top 10 Target, 2015
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Valeant Pharmaceuticals International, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Valeant Pharmaceuticals International, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top